Whole-genome sequencing and comparative genomic analysis of Bordetella pertussis isolates from the 2007-2008 epidemic in Israel Academic Article uri icon

abstract

  • Since our report of genomic epidemiology of Bordetella pertussis in Australia in this Journal earlier this year, 1 we have now investigated the genetic variations of B. pertussis in Israel. Israel has been using acellular vaccine (ACV) since 2002. 1 In Israel, there are currently two ACV formulations, including: Infanrix (GlaxoSmithKline), containing detoxified pertussis toxin (Ptx), filamentous hemaggluttin (Fha) and pertactin (Prn); and Poliocel (Sanofi Pasteur), containing two additional fimbriae antigens (Fim2 and Fim3), which are administered to infants at 2, 4, 6 and 12 months, with boosters administered at 7 and 13 year olds (Boostrix, GlaxoSmithKline). Despite a national vaccination coverage rate of 95%, pertussis epidemics have been observed in 2004, 2007 and 2012. The incidence rate in the 2007 epidemic (37/100,000) was the highest in over 50 years. 2 We sequenced 19 B. pertussis strains …

publication date

  • January 1, 2017